

# *Generation of induced pluripotent stem cell (iPSC) lines from urine samples.*



*María Romero Muñoz*

*Master in Health Biotechnology, University Pablo de Olavide.*

*Department of Regeneration and Cell Therapy,*

*Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER)*

## **1.Introduction.**

**1.1 iPSC origin.**

**1.2. iPSC sources.**

**1.3. Methods to produce IPSC: Sendai Virus.**

**1.4. Advantages of this work. UDC.**

## **2. Material and methods.**

**2.1. Culture media and culture conditions and transfection**

**2.2. Alkaline Phosphatase staining Kit**

**2.3.Trilineage Diferentiation.**

**2.4. i009 line characterization. PCR,inmunofluorescence and Flow  
citometry.**

## **3. Actual results.**

**3.1 iPSC culture evolution**

**3.2 iPSC pluripotent results: PCR, viral vector absence, inmunofluorescence and  
Flow cytometry.**


**3.3. iPSC differentiation ability: Trilineage markers by  
inmunofluorescence.**

## **4. Conclusion and remarkable points.**

What are iPSCs?

# iPSCs

Induced Pluripotent Stem cells



# 1 .Introduction.


## 1.1 iPSC origin.



John B. Gurdon



S. Yamanaka




Yamanaka's factors:  
Oct3/4, Sox2, c-Myc y  
Klf4


### The Nobel Prize in Physiology or Medicine 2012



John B. Gurdon



John B. Gurdon eliminated the nucleus of a frog egg cell (1) and replaced it with the nucleus from a specialised cell taken from a tadpole (2). The modified egg developed into a normal tadpole (3). Subsequent nuclear transfer experiments have generated cloned mammals (4).




Shinya Yamanaka

Shinya Yamanaka studied genes that are important for stem cell function. When he transferred four such genes (1) into cells taken from the skin (2), they were reprogrammed into pluripotent stem cells (3) that could develop into all cell types of an adult mouse. He named these cells induced pluripotent stem (iPS) cells.

<https://healthmanagement.org/c/icu/news/the-nobel-assembly-at-karolinska-institutet-awarded-the-nobel-prize-in-physiology-or-medicine-2012>

## 1.2. iPSC sources.

- Skin: fibroblasts and keratinocytes.
- Peripheral blood cells.
- Umbilical cord blood.
- Extraembryonic tissues.
- Adipose tissue.



<https://www.wired.com/>


<https://www.istockphoto.com/>

Figures designed by <https://biorender.com/>



# 1.3. Methods to produce iPSC: Sendai Virus.



Product	Qty	Cat. No.
CytoTune™ -iPS 2.0 Sendai Reprogramming Kit	1 pack (1 vial of each vector)	A16517
CytoTune™ -iPS 2.0 Sendai Reprogramming Kit	3 pack (3 vials of each vector)	A16518




CytoTune™ 2.0 KOS
CytoTune™ 2.0 hc-Myc
CytoTune™ 2.0 hKlf4



# 1.4. Advantages of this work. UDC.

Human urinary system



**Urine cells are fully functional**

2000 to 7000 cells downstream of the urinary tract are excreted in the urine



**Easy collection**


**Without ethical impediments**

## 2. Material and methods

- **Isolation and cultivation UDC.**
- **Transfection with sendai**
- **iPSC line maintenance.**
- **iPSC line characterization: alkaline phosphatase PCR, Flow cytometry immunofluorescence**
- **Differentiation capacity (Trilineage differentiation): specific culture media kit, PCR and immunofluorescence**




# 2.1. Culture media and culture conditions and transfection.



Figures designed by <https://biorender.com/>

## 2.2. Alkaline Phosphatase staining Kit.



Wash with PBS


Fix the cells with 4% PFA, 5 min,  
Room temperature.

Wash PBS-Tween 2x2min

Add AP substrate solution 20 min,  
room temperatura, dark


Wash with PBS

Take picture of the cells




## 2.3. Line characterization. Trilineage differentiation.


### Protocol Diagram



# 2.4. i009 line characterization: PCR.



## 2.4. i009 line characterization: Immunofluorescence.



## 2.3. i009 line characterization: Flow Citometry

Cells tripsinization

Final concentration  $10^6$  cells/ml



5 $\mu$ l isotipe

20 $\mu$ l pluripotency markers

20' in dark

Centrifugation and wash with PBS







Add 1ml of PBS









Pluripotency  
markers

**TRA-60**  
**SSEA-4**

### 3.1 iPSC culture evolution.



### 3.1 iPSC culture evolution.



**i009 pass 22 alkaline phosphatase assay**




## 3.2 Viral vector absence.

### Viral load control











### i009 pase 16



# 3.2 iPSC pluripotency results: PCR

## Pluripotency genes










OCT3		221pb
SOX2		437pb
NANOG		405pb
TELO		712 pb
HLA-A		197pb
HLA-B		130 pb
HLA-C		151pb
$\beta$ -ACTIN		206pb

### 3.2 iPSC pluripotent results: pluripotency markers by immunofluorescence.


TRA81  
Hoechst 33342

TRA60  
Hoechst 33342




SSEA4  
Hoechst 33342



### 3.2 iPSC pluripotent results: pluripotency markers by immunofluorescence.






## 3.2 iPSC pluripotent results: pluripotency markers by Flow cytometry.



### Histogram Statistics

File: i009 P20\_CN.001  
 Acquisition Date: 10-Feb-20  
 Gated Events: 5420  
 Total Events: 6645

Marker	Events	% Gated	% Total
All	5420	100.00	81.57
M1	177	3.27	2.66






### Histogram Statistics

File: i009 P20\_CP TRA60.002  
 Acquisition Date: 10-Feb-20  
 Gated Events: 6084  
 Total Events: 7912

Marker	Events	% Gated	% Total
All	6084	100.00	76.90
M1	276	4.54	3.49

TRA 60




### Histogram Statistics

File: i009 P20\_TRA60.003  
 Acquisition Date: 10-Feb-20  
 Gated Events: 5982  
 Total Events: 7604

Marker	Events	% Gated	% Total
All	5982	100.00	78.67
M1	5210	87.09	68.52


## 3.2 iPSC pluripotent results: pluripotency markers by Flow cytometry.



Histogram Statistics

File: i009 P20\_CN.001  
 Acquisition Date: 10-Feb-20  
 Gated Events: 5845  
 Total Events: 6645

Marker	Events	% Gated	% Total
All	5845	100.00	87.96
M1	0	0.00	0.00




Histogram Statistics

File: i009 P20\_Ssea4.006  
 Acquisition Date: 10-Feb-20  
 Gated Events: 6207  
 Total Events: 7071

Marker	Events	% Gated	% Total
All	6207	100.00	87.78
M1	174	2.80	2.46

SSEA-4




Histogram Statistics


File: i009 P20\_Ssea4\_007  
 Acquisition Date: 10-Feb-20  
 Gated Events: 6031  
 Total Events: 6788

Marker	Events	% Gated	% Total
All	6031	100.00	88.85
M1	5524	91.59	81.38

### 3.3. iPSC differentiation ability: Trilineage markers by PCR.



### 3.3. iPSC differentiation ability: Trilineage markers by immunofluorescence.






## 4. Conclusions and remarkable points.



It has been possible to isolate, cultivate and transform UDCs into iPSCs as a non invasive method.




The generation of iPSC lines represents a great advance for cell therapy and tissues bioengineering.




We need to further characterize our iPSC line, by studying its karyotype and testing its ability to form teratomas in vivo.

Also we have to study possible anomalies in the culture and its karyotype.



To apply this procedure in cell therapy, we should repeat all culture processes under Good Manufacturing Practices (GMP).





Thanks!  
Any questions?